Research
CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
BioPharma Dive · By Ben Fidler ·
The Brief
- CG Oncology reported that its therapy cretostimogene cut the risk of recurrence by 68% when given after surgery in a key bladder cancer trial.
- The results were reported as far exceeding Wall Street's expectations and lifted the company's shares.
- The source describes the results as 'exceptional'.
Why it matters
The trial reports a large reduction in bladder cancer recurrence after surgery, which could shape how adjuvant treatment is evaluated for this disease.
Who’s affected
- bladder cancer patients and clinicians
- investors following biotechnology companies
- #bladder cancer
- #oncology
- #clinical trial
- #cretostimogene
- #recurrence
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.